Clinical Trial Update: Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating Kadcyla (ado-trastuzumab emtansine) and neratinib for interception of HER2-positive breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• neratinib (neratinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING